Antineoplastic Combined Chemotherapy Protocols
"Antineoplastic Combined Chemotherapy Protocols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
| Descriptor ID |
D000971
|
| MeSH Number(s) |
E02.183.750.500 E02.319.077.500 E02.319.310.037
|
| Concept/Terms |
Antineoplastic Combined Chemotherapy Protocols- Antineoplastic Combined Chemotherapy Protocols
- Combined Antineoplastic Agents
- Antineoplastic Agents, Combined
- Agent, Combined Antineoplastic
- Agents, Combined Antineoplastic
- Antineoplastic Agent, Combined
- Combined Antineoplastic Agent
- Antineoplastic Combined Chemotherapy Regimens
- Drug Combinations, Antineoplastic
- Anticancer Drug Combinations
- Anticancer Drug Combination
- Drug Combination, Anticancer
- Drug Combinations, Anticancer
- Antineoplastic Drug Combinations
- Antineoplastic Drug Combination
- Combinations, Antineoplastic Drug
- Drug Combination, Antineoplastic
Antineoplastic Chemotherapy Protocols- Antineoplastic Chemotherapy Protocols
- Antineoplastic Chemotherapy Protocol
- Chemotherapy Protocol, Antineoplastic
- Protocol, Antineoplastic Chemotherapy
- Protocols, Antineoplastic Chemotherapy
- Cancer Chemotherapy Protocols
- Cancer Chemotherapy Protocol
- Chemotherapy Protocol, Cancer
- Chemotherapy Protocols, Cancer
- Protocol, Cancer Chemotherapy
- Protocols, Cancer Chemotherapy
- Chemotherapy Protocols, Antineoplastic
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Combined Chemotherapy Protocols".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Combined Chemotherapy Protocols".
This graph shows the total number of publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in this website by year, and whether "Antineoplastic Combined Chemotherapy Protocols" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 9 | 3 | 12 |
| 1996 | 10 | 4 | 14 |
| 1997 | 7 | 1 | 8 |
| 1998 | 12 | 3 | 15 |
| 1999 | 9 | 3 | 12 |
| 2000 | 8 | 3 | 11 |
| 2001 | 5 | 3 | 8 |
| 2002 | 8 | 7 | 15 |
| 2003 | 8 | 11 | 19 |
| 2004 | 7 | 8 | 15 |
| 2005 | 11 | 6 | 17 |
| 2006 | 14 | 7 | 21 |
| 2007 | 16 | 5 | 21 |
| 2008 | 25 | 8 | 33 |
| 2009 | 19 | 8 | 27 |
| 2010 | 19 | 11 | 30 |
| 2011 | 19 | 13 | 32 |
| 2012 | 15 | 6 | 21 |
| 2013 | 22 | 5 | 27 |
| 2014 | 31 | 12 | 43 |
| 2015 | 25 | 14 | 39 |
| 2016 | 13 | 15 | 28 |
| 2017 | 22 | 15 | 37 |
| 2018 | 34 | 16 | 50 |
| 2019 | 30 | 12 | 42 |
| 2020 | 25 | 18 | 43 |
| 2021 | 16 | 26 | 42 |
| 2022 | 9 | 34 | 43 |
| 2023 | 3 | 37 | 40 |
| 2024 | 23 | 22 | 45 |
| 2025 | 10 | 2 | 12 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Profiles.
-
Phase 2 trial of veliparib, local irradiation, and temozolomide in patients with newly diagnosed high-grade glioma: a Children's Oncology Group study. Neuro Oncol. 2025 May 15; 27(4):1092-1101.
-
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial. J Natl Cancer Inst. 2025 May 01; 117(5):889-897.
-
Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial. Breast Cancer Res Treat. 2025 Jul; 212(1):57-69.
-
Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and progression-free survival in patients with hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2025 Jul; 212(1):71-78.
-
Current and emerging treatment perspectives for adults with Waldenstr?m macroglobulinemia. Expert Rev Anticancer Ther. 2025 May; 25(5):485-497.
-
Treatment refractoriness and response rates in patients with relapsed/refractory multiple myeloma: a retrospective analysis of real-world data. Cancer Treat Res Commun. 2025; 43:100921.
-
How I treat patients with AML using azacitidine and venetoclax. Blood. 2025 Mar 20; 145(12):1237-1250.
-
Enhancement of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma. Clin Cancer Res. 2025 Mar 17; 31(6):975-982.
-
Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2- metastatic breast cancer: A Flatiron Health database analysis. Breast. 2025 Jun; 81:104448.
-
Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations. Blood Cancer J. 2025 Mar 15; 15(1):40.